Development of novel bone-targeted chloroquine conjugates to prevent bone resorption.
开发新型骨靶向氯喹结合物以防止骨吸收。
基本信息
- 批准号:9355087
- 负责人:
- 金额:$ 20.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-22 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAdverse drug effectAdverse effectsAdverse eventAffectAffinityAmericanAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAntibioticsAreaArthralgiaArthritisAutoimmune DiseasesBenchmarkingBindingBiological AssayBlindnessBone DiseasesBone ResorptionBone SurfaceBone necrosisCarbamatesCartilageChemistryChloroquineDataDevelopmentDiseaseDisease remissionDoseDrug DesignDrug TargetingDrug usageEnzyme-Linked Immunosorbent AssayEuropeFemoral FracturesFrozen SectionsFutureGenerationsHumanHydroxychloroquineHyperparathyroidismImageIn VitroIndocyanine GreenInflammationInjectableJawJointsKidneyKnee jointLabelLeadLeftLimb structureLinkMethodologyMethodsMethotrexateModelingMonitorMusNormal tissue morphologyOsteoclastsOsteogenesisOsteoporosisPatientsPharmaceutical PreparationsPhysiciansPhysiologic calcificationPlasticizersPostmenopausal OsteoporosisPropertyReportingRheumatoid ArthritisRiskRouteSafetySecond lumbar vertebraSerumSiteSynovitisTNF geneTechnetiumTechnologyTestingTherapeutic AgentsTissuesToxic effectTransgenic MiceWorkWrist jointZoledronateanalogankle jointbasebisphosphonatebonebone imagingbone lossbone turnoverdesigndosagein vivoin vivo imaging systeminfrared microscopyinhibitor/antagonistjoint destructionmicroCTmouse modelnovelnovel strategiesnovel therapeuticspreventscale upsuccesstibiawillingness
项目摘要
ABSTRACT
Rheumatoid arthritis (RA) is a common autoimmune disease, which can cause devastating joint destruction
and generalized and localized osteoporosis. Generally, there is no cure for RA, although a variety of drugs can
reduce inflammation and joint destruction, including chloroquine (CQ) and hydroxychloroquine (HCQ). Many
anti-RA drugs have severe side effects, for example CQ can result in renal toxicity and blindness in up to 0.5-
1% of patients. HCQ has a slightly lower toxicity profile and for this reason it replaced CQ for the treatment of
RA in the US and Europe many years ago. We reported recently that CQ, but not HCQ, prevents bone
resorption and osteoporosis in mouse models of postmenopausal osteoporosis and hyperparathyroidism. An
attractive strategy to minimize side effects of drugs used to treat bone diseases is to administer them in a form
that targets them to bone. This could allow drugs to be given to patients at doses with reduced risk of side
effects, while also delivering effective concentrations specifically to bone. Based on the high bone affinity of
bisphosphonates (BPs) that are currently used to osteoporosis, we have generated a Bone-Targeted CQ
(BTCQ) analog using a BP that binds avidly to bone, but does not inhibit bone resorption, which we attached to
CQ through degradable carbamate linker chemistry. We have confirmed that BTCQ has high affinity for bone
and high potency to inhibit osteoclast formation and bone resorption at 3-10-fold lower concentrations than CQ
in vitro. It also inhibited PTH-induced bone resorption in vivo in mice at significantly lower concentrations than
CQ. We now plan to: 1) Scale up the existing synthetic route, optimize purification methods to prepare
sufficient quantities of BTCQ for examination of its in vivo efficacy in an animal model of RA and test the
distribution and cellular localization of fluorescently-labeled bisphosphonates in vivo as an early mechanistic
approximation of the PK of BTCQ and potentially of the released CQ; 2) Examine the efficacy of these novel
BTCQ conjugates to prevent the development of joint inflammation and destruction in a TNF transgenic mouse
model of RA. Success with these studies could then lead to the development of a novel therapy for RA patients
and later to the generation of other types of bone-targeted drugs, including chemotherapeutics and antibiotics,
using this new conjugation technology.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT K BOECKMAN其他文献
ROBERT K BOECKMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT K BOECKMAN', 18)}}的其他基金
Study of osteoblast regulation in TNF-mediated bone loss
TNF介导的骨丢失中成骨细胞调节的研究
- 批准号:
8891736 - 财政年份:2013
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
2175770 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
3278043 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
3278052 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
6342785 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
3278051 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
3278053 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别:
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS
新型生物活性天然产物的合成
- 批准号:
2684735 - 财政年份:1982
- 资助金额:
$ 20.33万 - 项目类别: